Literature DB >> 34651215

Discriminating surgical bed cysts from bacterial brain abscesses after Carmustine wafer implantation in newly diagnosed IDH-wildtype glioblastomas.

Alexandre Roux1,2,3, Hichem Ammar1,2, Alessandro Moiraghi1,2, Sophie Peeters4, Marwan Baroud1,2, Gilles Zah-Bi1,2, Joseph Benzakoun2,3,5, Eduardo Parraga1,2, Catherine Oppenheim2,3,5, Chiara Benevello1,2, Fabrice Chretien2,6, Pascale Varlet2,3,6, Frédéric Dhermain7, Edouard Dezamis1,2,3, Marc Zanello1,2,3, Johan Pallud8,9,10.   

Abstract

Carmustine wafers can be implanted in the surgical bed of high-grade gliomas, which can induce surgical bed cyst formation, leading to clinically relevant mass effect. An observational retrospective monocentric study was conducted including 122 consecutive adult patients with a newly diagnosed supratentorial glioblastoma who underwent a surgical resection with Carmustine wafer implantation as first line treatment (2005-2018). Twenty-two patients (18.0%) developed a postoperative contrast-enhancing cyst within the surgical bed: 16 surgical bed cysts and six bacterial abscesses. All patients with a surgical bed cyst were managed conservatively, all resolved on imaging follow-up, and no patient stopped the radiochemotherapy. Independent risk factors of formation of a postoperative surgical bed cyst were age ≥ 60 years (p = 0.019), number of Carmustine wafers implanted ≥ 8 (p = 0.040), and partial resection (p = 0.025). Compared to surgical bed cysts, the occurrence of a postoperative bacterial abscess requiring surgical management was associated more frequently with a shorter time to diagnosis from surgery (p = 0.009), new neurological deficit (p < 0.001), fever (p < 0.001), residual air in the cyst (p = 0.018), a cyst diameter greater than that of the initial tumor (p = 0.027), and increased mass effect and brain edema compared to early postoperative MRI (p = 0.024). Contrast enhancement (p = 0.473) and diffusion signal abnormalities (p = 0.471) did not differ between postoperative bacterial abscesses and surgical bed cysts. Clinical and imaging findings help discriminate between surgical bed cysts and bacterial abscesses following Carmustine wafer implantation. Surgical bed cysts can be managed conservatively. Individual risk factors will help tailor their steroid therapy and imaging follow-up.
© 2021. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.

Entities:  

Keywords:  Brain abscess; Carmustine wafer; Glioblastoma; Neurosurgery; Surgical bed cyst

Mesh:

Substances:

Year:  2021        PMID: 34651215     DOI: 10.1007/s10143-021-01670-7

Source DB:  PubMed          Journal:  Neurosurg Rev        ISSN: 0344-5607            Impact factor:   3.042


  17 in total

1.  Cytotoxic chemotherapeutic management of newly diagnosed glioblastoma multiforme.

Authors:  Camilo E Fadul; Patrick Y Wen; Lyndon Kim; Jeffrey J Olson
Journal:  J Neurooncol       Date:  2008-08-20       Impact factor: 4.130

2.  Tumor bed cyst formation after BCNU wafer implantation: report of two cases.

Authors:  H H Engelhard
Journal:  Surg Neurol       Date:  2000-03

3.  A phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (Gliadel wafers) in patients with primary malignant glioma.

Authors:  Manfred Westphal; Dana C Hilt; Enoch Bortey; Patrick Delavault; Robert Olivares; Peter C Warnke; Ian R Whittle; Juha Jääskeläinen; Zvi Ram
Journal:  Neuro Oncol       Date:  2003-04       Impact factor: 12.300

4.  Management of tumor bed cysts after chemotherapeutic wafer implantation. Report of four cases.

Authors:  Matthew J McGirt; Alan T Villavicencio; Ketan R Bulsara; Henry S Friedman; Allan H Friedman
Journal:  J Neurosurg       Date:  2002-05       Impact factor: 5.115

5.  A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival.

Authors:  M Lacroix; D Abi-Said; D R Fourney; Z L Gokaslan; W Shi; F DeMonte; F F Lang; I E McCutcheon; S J Hassenbusch; E Holland; K Hess; C Michael; D Miller; R Sawaya
Journal:  J Neurosurg       Date:  2001-08       Impact factor: 5.115

6.  Gliadel (BCNU) wafer plus concomitant temozolomide therapy after primary resection of glioblastoma multiforme.

Authors:  Matthew J McGirt; Khoi D Than; Jon D Weingart; Kaisorn L Chaichana; Frank J Attenello; Alessandro Olivi; John Laterra; Lawrence R Kleinberg; Stuart A Grossman; Henry Brem; Alfredo Quiñones-Hinojosa
Journal:  J Neurosurg       Date:  2009-03       Impact factor: 5.115

Review 7.  Pharmacokinetics of the carmustine implant.

Authors:  Alison B Fleming; W Mark Saltzman
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

Review 8.  Safety profile of carmustine wafers in malignant glioma: a review of controlled trials and a decade of clinical experience.

Authors:  Michael Sabel; Alf Giese
Journal:  Curr Med Res Opin       Date:  2008-10-20       Impact factor: 2.580

9.  The influence of maximum safe resection of glioblastoma on survival in 1229 patients: Can we do better than gross-total resection?

Authors:  Yan Michael Li; Dima Suki; Kenneth Hess; Raymond Sawaya
Journal:  J Neurosurg       Date:  2015-10-23       Impact factor: 5.115

10.  Feasibility, Safety and Impact on Overall Survival of Awake Resection for Newly Diagnosed Supratentorial IDH-Wildtype Glioblastomas in Adults.

Authors:  Alessandro Moiraghi; Alexandre Roux; Sophie Peeters; Jean-Baptiste Pelletier; Marwan Baroud; Bénédicte Trancart; Catherine Oppenheim; Emmanuèle Lechapt; Chiara Benevello; Eduardo Parraga; Pascale Varlet; Fabrice Chrétien; Edouard Dezamis; Marc Zanello; Johan Pallud
Journal:  Cancers (Basel)       Date:  2021-06-10       Impact factor: 6.575

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.